Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Neoplasms

Treatments: Drug: BMS-907351 (XL184)

Study type: Interventional

Funder types: Industry

Identifiers

NCT01018745

CA205-001

Details and patient eligibility

About

The purpose of this clinical study is to establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (or dose range as appropriate) of BMS-907351 (XL184) when administered orally on a once daily schedule in subjects with advanced or metastatic solid tumors.

Enrollment: 3 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate
• Life expectancy of at least 3 months
• Eastern Cooperative Oncology Group performance 0-2

Exclusion criteria

• Subject has uncontrolled intercurrent illness

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

3 participants in 1 patient group

BMS-907351 (XL184)

Experimental group

Treatment:

Drug: BMS-907351 (XL184)